Prabowo Widodo
Science Corporation, a pioneering startup at the forefront of brain-computer interface (BCI) technology, has announced a landmark achievement with the receipt of CE Mark approval from Europe’s stringent medical device regulator. This pivotal authorization permits the company to commence sales of PRIMA, an innovative BCI device designed to restore vision lost due to age-related macular degeneration (AMD). The announcement marks a significant step not only for Science Corporation but for the broader field of neurotechnology, offering a tangible solution to a widespread and debilitating condition.
The European approval is complemented by parallel progress in the United States, where the PRIMA device has been granted a crucial designation by the US Food and Drug Administration (FDA). This designation represents the initial phase toward an expedited regulatory review process, potentially accelerating the device’s availability in the American market. Furthermore, this fast-tracked pathway is anticipated to pave the way for PRIMA’s application in treating two distinct, rare forms of blindness, underscoring the versatility and potential breadth of its therapeutic utility. This dual-continent regulatory momentum positions Science Corporation at the vanguard of commercializing advanced neuroprosthetics.
The Global Burden of Age-Related Macular Degeneration
Age-related macular degeneration is a leading cause of irreversible vision loss among individuals aged 50 and older, profoundly impacting quality of life for millions worldwide. The condition specifically targets the macula, the central part of the retina responsible for sharp, detailed vision necessary for tasks like reading, recognizing faces, and driving. As the disease progresses, the light-sensitive cells within the macula deteriorate, leading to blurred central vision or blind spots.
Globally, an estimated 196 million people were living with AMD in 2020, a number projected to reach 288 million by 2040. In Europe, where PRIMA has just received approval, millions are affected, with prevalence rates increasing significantly with age. Similarly, in the United States, over 11 million people have AMD, and this figure is expected to double by 2050. The disease manifests in two primary forms: dry AMD, which accounts for about 85-90% of cases and involves the gradual thinning of the macula, and wet AMD, a more severe form characterized by abnormal blood vessel growth under the retina that leaks fluid or blood, causing rapid and severe vision loss.
Current treatments for wet AMD, such as anti-VEGF injections, can slow progression and sometimes improve vision, but they are invasive, require frequent administration, and are not curative. For dry AMD, treatment options are even more limited, primarily focusing on nutritional supplements to slow progression, but there is no cure to restore lost vision. This significant unmet medical need underscores the transformative potential of PRIMA, which offers a restorative approach rather than merely a preventative or slowing one. The ability to regain functional vision for individuals who have lost it due to AMD represents a paradigm shift in ocular care.
How PRIMA Works: A Glimpse into Vision Restoration
The PRIMA device represents a sophisticated fusion of microelectronics and neurobiology, designed to bypass the damaged photoreceptors in the macula and directly stimulate the remaining healthy retinal cells. The process begins with an outpatient surgical procedure, typically lasting about an hour, during which a miniature chip is meticulously implanted into the back of the patient’s eye, specifically beneath the retina in the macular region. This subretinal implant is a marvel of miniaturization, housing an array of thousands of tiny photodiodes that act as artificial photoreceptors.
Following the implantation, patients are equipped with specialized camera-equipped glasses. These glasses serve as the external interface, capturing the visual world in real-time. The captured images are then processed and wirelessly transmitted to the implanted chip. Upon receiving these signals, the chip’s photodiodes convert the light patterns into electrical impulses. These impulses are then directed to the surrounding healthy retinal neurons, which, in turn, relay the signals through the optic nerve to the brain. The brain then interprets these electrical signals as visual information, effectively restoring a form of functional vision.
Max Hodak, founder and CEO of Science Corporation, emphasizes the profound impact of this technology on patients’ lives. "One of our patients in France finished a 300-page novel a little while ago, and sent us the book," Hodak recounted to TechCrunch, illustrating the device’s capability to restore detailed vision. He further added, "We have a sketch on the wall [that] one of our patients drew of the Sydney Opera House. There are videos of patients playing crossword puzzles and filling in Sudoku." These anecdotes highlight not just the restoration of basic sight but the return of complex visual functions that enable engagement with hobbies, reading, and daily activities, significantly enhancing independence and quality of life. The learning curve for patients involves adapting to the new visual input, often requiring rehabilitation to interpret the signals effectively.
A Visionary Leader: Max Hodak’s Journey from Neuralink to Science
The driving force behind Science Corporation is Max Hodak, a figure well-known in the burgeoning BCI landscape. Hodak co-founded Neuralink alongside Elon Musk and served as its president until his departure in 2021. While Neuralink garnered significant media attention for its ambitious long-term goals of direct brain-computer interfaces for various neurological applications, Hodak’s vision for Science took a slightly different, albeit complementary, path.
Upon establishing Science, Hodak articulated a plan to develop novel BCIs based on a hybrid approach, integrating silicon chips with living cells. However, he recognized the critical need for a sustainable business model to underpin such long-term, capital-intensive research and development. This strategic imperative led to the company’s initial focus on a commercially viable product that could generate substantial revenue while proving out the company’s operational and regulatory processes.
Hodak’s philosophy is rooted in the belief that the BCI space needs a robust financial foundation to thrive. "The thing that the space needs is a company making $100 million a year of revenue," Hodak stated. "There’s this risk that the whole thing enters a winter, and so we think it’s important to build a sustainable business as we develop these longer-term technologies." This pragmatic approach contrasts with some of the more speculative ventures in the BCI sector, aiming to de-risk future innovations by securing early commercial success. The restoration of vision to the blind, particularly those with conditions stemming from photoreceptor damage, emerged as the most promising avenue for achieving this sustainability.
Strategic Acquisition and Commercialization Pathway
Science Corporation’s journey to commercializing PRIMA involved a crucial strategic maneuver: the acquisition of Pixium Vision, a French company, in 2024. Pixium Vision had been instrumental in developing the core PRIMA technology, having conducted extensive research and early clinical trials. Hodak and his team, after exploring various approaches to vision restoration, concluded that Pixium’s technology offered the most viable path forward. The acquisition allowed Science to integrate Pixium’s foundational work with its own advanced internal platform.
This integration was critical for streamlining the product’s evolution and preparing it for the rigorous demands of regulatory approval and subsequent commercialization. Science Corporation leveraged its expertise to enhance the documentation, refine the device’s capabilities, and navigate the complex labyrinth of medical device regulations in both Europe and the United States. This synergistic approach accelerated PRIMA’s journey from a promising technology to a market-ready product.
The commercial rollout of PRIMA is expected to begin in Germany, a country where the device’s clinical trials were conducted, establishing a strong foundation of data and medical familiarity. Science Corporation anticipates the first surgical procedures in Germany could take place as early as September. However, the cost of such advanced medical technology is substantial, with each PRIMA device projected to cost in the "hundreds of thousands of dollars." This high price point necessitates extensive discussions with healthcare providers and insurance companies across Europe to establish reimbursement pathways, a critical step for broad patient access. These negotiations are currently underway with Science and its medical partners, aiming to make this life-changing technology accessible to those who need it most.
Chronology of Milestones: A Path to Vision Restoration
- 2021: Max Hodak departs Neuralink, co-founding Science Corporation with a vision for bio-hybrid BCIs and a pragmatic approach to commercialization.
- Early Years (2021-2023): Science Corporation focuses on developing its internal platform and identifying a sustainable business model, ultimately honing in on vision restoration.
- 2024: Science Corporation acquires Pixium Vision, integrating its PRIMA technology and accelerating development for regulatory approval.
- Recent Past: Science Corporation leverages its internal platform to refine PRIMA, generate comprehensive documentation, and prepare for market entry.
- Present Day: CE Mark approval granted by Europe’s medical device regulator, allowing sales of PRIMA in the European Union.
- Present Day: US Food and Drug Administration (FDA) grants PRIMA a designation for expedited regulatory review, aiming for treatment of two rare forms of blindness.
- Upcoming (September): Anticipated commencement of the first PRIMA implantation procedures in Germany, following ongoing reimbursement discussions.
- Ongoing: Development of a new, improved chip for PRIMA, aiming for enhanced vision capabilities and reduced form factor of the glasses (less reliance on battery packs).
- Long-Term: Collaboration with Dr. Murat Günel of Yale Medical School to develop procedures for human trials of a directly implanted bio-hybrid brain sensor, representing Science’s ultimate long-term BCI ambition.
Future Enhancements and Broader BCI Ambitions
Science Corporation is not resting on its laurels. The company is already planning significant improvements to the PRIMA system. Future iterations aim to integrate a new, more advanced chip that promises to enhance the visual capabilities offered to patients. Concurrently, efforts are focused on refining the form factor of the accompanying glasses. Currently, these glasses require an external battery pack, which, while functional, adds to the bulk. The long-term goal is to achieve a sleeker design, perhaps akin to Meta’s AR glasses, offering a more discreet and comfortable user experience. This involves overcoming significant engineering challenges related to power consumption and computational requirements, which are substantially greater for PRIMA’s advanced visual processing.
Beyond vision restoration, Science Corporation remains committed to its foundational mission of developing advanced bio-hybrid brain sensors. This ambitious long-term project involves a critical collaboration with Dr. Murat Günel, the esteemed chair of Yale Medical School’s Department of Neurosurgery. Together, they are developing the necessary procedures for human trials of a directly implanted bio-hybrid brain sensor. This represents the ultimate frontier of Hodak’s vision: integrating living biological components with advanced silicon to create BCIs that are more seamlessly integrated with neural tissue, potentially offering unprecedented capabilities for treating a wide array of neurological conditions, from paralysis to neurodegenerative diseases.
Hodak reiterates the strategic importance of PRIMA’s commercial success in funding these more speculative, long-term endeavors. "Bringing PRIMA to market is the most important thing for the company, because we don’t get to do the bio hybrid stuff long term if you don’t have a great vision business," he asserted. "That’s what’s really financing the rest of it – that’s the thing that investors know how to build spreadsheets around." This clear articulation of financial strategy underscores the intricate balance between pioneering innovation and commercial viability in the high-stakes world of medical technology.
Implications for the BCI Landscape and Medical Innovation
The CE Mark approval for PRIMA is more than just a win for Science Corporation; it is a significant validation for the entire brain-computer interface field. It demonstrates that BCI technology can move beyond research labs and into clinical application, offering tangible therapeutic benefits. This success could catalyze further investment and research into BCIs for a myriad of conditions, from restoring motor function in paralyzed individuals to addressing cognitive impairments.
Ethical considerations, while less pronounced for therapeutic vision restoration than for broader neuro-enhancement, remain an important aspect of BCI development. Ensuring patient safety, data privacy, and informed consent will be paramount as these technologies become more widespread. Science Corporation’s rigorous regulatory approval process underscores a commitment to these principles.
Economically, the market for vision restoration devices is substantial, given the global prevalence of AMD and other forms of blindness. The successful commercialization of PRIMA could establish a lucrative niche, paving the way for other companies to pursue similar restorative technologies. The blend of advanced surgical techniques, sophisticated microelectronics, and AI-driven image processing embodied by PRIMA represents the cutting edge of medical innovation.
In conclusion, Science Corporation’s achievement with PRIMA marks a pivotal moment in medical technology. By securing European regulatory approval and advancing through the FDA’s expedited pathway, the company is poised to offer renewed sight to millions suffering from debilitating vision loss. This success not only fulfills an immediate medical need but also strategically funds the development of even more ambitious bio-hybrid brain-computer interfaces, promising a future where the integration of human biology and advanced technology could unlock unprecedented therapeutic possibilities.
